
Experts examine the use of Technosphere insulin, how it is delivered to the body, and the qualities of an ideal rapid-acting insulin analog in type 1 and type 2 diabetes.

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Experts examine the use of Technosphere insulin, how it is delivered to the body, and the qualities of an ideal rapid-acting insulin analog in type 1 and type 2 diabetes.

Drs Diana Isaacs and Natalie Bellini discuss the limitations of injectable insulins in achieving time-in-range and glucose targets in type 1 and type 2 diabetes.

Expert health care practitioners review the different types of insulin formulations available for people with T1D or T2D, including regular and rapid-acting.

Drs Diana Isaacs and Natalie Bellini discuss selecting the right insulin delivery method for patients with diabetes, and the challenges that arise with insulin injectables.

Drs Diana Isaacs and Natalie Bellini provide an overview of the types of insulin delivery systems used in type 1 diabetes (T1D) and type 2 diabetes (T2D), including injections, patches, and inhalable insulin.

In this special edition episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, break down what the approval of teplizumab means for type 1 diabetes. During the episode, hosts take a deep dive into type 1 diabetes staging and hypothesize around the role of CDCES in educating primary care and other specialties to optimize the potential of teplizumab.

In this episode, our hosts are joined by Lydia Alexander, MD, president-elect of the Obesity Medicine Association, to discuss the updates in the landscape of obesity management as well as a deep dive into the recent American Gastroenterological Association guidelines for pharmacological management and the OMA's annual meeting.

In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the ongoing GLP-1 RA shortage and whether or not celebrities using these agents for weight loss is a real issue in the community as well as provide insight into their top takeaways from the ADA/KDIGO consensus report.

In this special edition episode of Diabetes Dialogue, our hosts break down their top clinical takeaways from the European Association for the Study of Diabetes 2022 annual meeting, new data from the FLASH-UK trial, the global launch of Dexcom G7, and the announcement of US availability for the FreeStyle Libre 3.

In this regularly scheduled September 2022 episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, provide their own perspective on DIY looping based on the results of a recent study published in the New England Journal of Medicine and also break down a new set of consensus recommendations for the use of automated insulin delivery (AID) systems in clinical practice published in Endocrine Reviews, which Isaacs helped compose as a member of the writing committee.

In this episode of Diabetes Dialogue, which was filmed just days after the conclusion of ADCES 22, our hosts take the time to dive deeper into the conference, their favorite sessions, and how the ADCES meetings have evolved to the changing role of diabetes care and education specialists over the years.

In this article, readers will find a collection of the on-site coverage of the Association of Diabetes Care and Education Specialist (ADCES) 2022 annual meeting from Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives.

In this edition of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives, which was filmed on-site at ADCES 22, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down with Jennifer Clements, PharmD, following her sessions to discuss her work, her upcoming research interests, and ongoing trends in the field of diabetes management.

In this episode, the hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down with ADCES 2022 Diabetes Care and Education Specialist of the Year Anastasia Albanese-O’Neill, PhD, to discuss her inspiration, her work within the field, and insight into the project she has decided to focus on during her year as ADCES Diabetes Care and Education Specialist of the Year.

In this special edition ADCES 22 episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, are joined by David Walton, CEO of the T1D Exchange, who takes our hosts on a deep dive into the history of the organization, what it is doing right now to improve patient care, and how it expects to grow and improve management of type 1 diabetes into the future.

In this special edition of Diabetes Dialogue recorded on-site at ADCES 22, our hosts are joined by Korey Hood, PhD, a staff psychologist and professor at Stanford University. Founder of DiabetesWise and DiabetesWisePro, Hood talks to Diana Isaacs, PharmD, and Natalie Bellini, DNP, about his efforts and how the online resources are pushing care forward.

For the July 2022 episode of Diabetes Dialogue: Therapeutics, Technology, and Real-World Perspectives, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down to provide perspective on the latest advances in the fight to cure type 1 diabetes and offer insight into their experiences at the Practical Ways to Achieve Targets in Diabetes Care Conference held in Keystone, CO in mid-July.

In this episode, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss their experiences with prescribing tirzepatide (Mounjaro) and what issues patients have encountered, the prospect of new biosimilar insulins that may be coming to the market, and the misdiagnosis of type 1 diabetes in adult patients.

In the fourth and final episode from ADA 2022, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, take a deep dive into the meeting from their perspectives as a clinical pharmacy specialist and a nurse practitioner, including their picks for the most exciting advances in diabetes technology to come from the year’s largest diabetes meeting.

In the third special edition episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives from ADA 2022, Jasmine Gonzalvo, PharmD, joins hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss prevailing barriers in diabetes management, including access to new pharmacologic agents as well as newer diabetes technologies.

In our second special edition episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives from ADA 2022, hosts Drs. Diana Isaacs and Natalie Bellini are joined by Gary Scheiner, MS, CDE. Clinical director of Integrated Diabetes Services, author of multiple books, including Think Like a Pancreas: A Practical Guide to Managing Diabetes with Insulin, and former Diabetes Educator of the Year, Scheiner joins Diabetes Dialogue to provide a deep dive into the largest diabetes meeting of the year from the view of a diabetes care and education specialist.

In the first of 4 special edition ADA 2022 episodes, hosts Drs. Diana Isaacs and Natalie Bellini take on the role of interviewers and discuss CGM uptake in primary care with Drs. Sean and Tamara Oser. Later in the episode, the pair provide perspective on their experiences with Beta Bionics's Insulin-Only Bionic Pancreas.

In this episode of Diabetes Dialogue, hosts Drs. Isaacs and Bellini take a deep dive into the tirzepatide approval, including discussions around the mechanism of action, dose titrations, and where it might fit in the upcoming ADA standards of care. Later in the episode, hosts recap their experiences from AACE 2022, which saw the release of new guidelines for NAFLD.

In this special edition ATTD Recap episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives, hosts Drs. Diana Isaacs and Natalie Bellini provide insight from ATTD 2022, including the latest updates in the world of diabetes smartphone apps, smart insulin pens, and CGM systems.

In the April 2022 edition of Diabetes Dialogue: Therapeutics, Technology, and Real-World Perspectives, hosts Drs. Diana Isaacs and Natalie Bellini discuss the implications of the FDA's approval of semaglutide 2.0 mg, the use of novel glycemic control metrics, and a preview of ATTD 2022.

The inaugural episode of Diabetes Dialogue features an introduction to hosts Diana Isaacs, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP, and Natalie Bellini, DNP, FNP-BC, and a discussion around recent regulatory news surrounding CGM devices in the US and Europe.